Somatus’ kidney care services and technology platform

Somatus is a McLean, Virginia-based kidney care organisation, operating a technology platform to predict disease and other ends.

Somatus says it provides care services to over 20,000 patients with chronic and end-stage kidney disease in six states.

Its RenallQ platform analyses multiple data sets to predict undiagnosed disease, as well as the course of its progression.

Since its foundation in 2016, the company says it has raised over $100mn in capital. Its latest Series C, announced last month, saw the company raise $64mn from lead investors Optum Ventures, Longitude Capital and Deerfield Management, alongside Town Hall Ventures, The Blue Venture Fund and Flare Capital Partners.

In a press release, Somatus Co-Founder and CEO, Ikenna Okezie, MD, said: “Since our inception, we have set out to do one thing: be the best provider of integrated care for those with or at risk of developing kidney disease. Fueled by the tenacity of our team, the trust of our patients, and the support of our partners and investors, we have made great strides in the pursuit of our mission and helped spur needed transformation in the kidney care sector. This investment allows us to accelerate those efforts while solidifying ourselves as a preferred partner for health plans and a trusted advocate for patients.”

The company said it would use the funding to scale nationally, while further investing in technology and product development.

“Somatus is at the forefront of revolutionary change in an industry that has forced patients to accept the status quo for far too long,” said Longitude Capital Managing Director, Gregory Grunberg, MD. “Somatus is transforming how the industry cares for patients with chronic kidney disease by not only meeting them where they are but also by aligning all kidney care stakeholders to support the health and wishes of patients. This patient-centric model is a win-win solution for patients, partners, and providers.”